In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human P-glycoprotein

Life Sciences

Volumn 86, Issue 23-24, 2010, Pages 899-905

  Zhang, Chunbo ^a   Kwan, Patrick ^a   Zuo, Zhong ^a   Baum, Larry ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Antiepileptic drugs; Blood brain barrier; Drug transport; Ethosuximide; P glycoprotein; Phenobarbital; Phenytoin

Indexed keywords

ETHOSUXIMIDE; GLYCOPROTEIN P; PHENOBARBITAL; PHENYTOIN;

ANIMAL CELL; ARTICLE; ASSAY; BIDIRECTIONAL TRANSPORT ASSAY; CONCENTRATION (PARAMETERS); CONCENTRATION EQUILIBRIUM TRANSPORT ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG TRANSPORT; ENDOTHELIUM CELL; GENETIC TRANSFECTION; IN VITRO STUDY; KIDNEY CELL; NONHUMAN; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SWINE;

SUS;

EID: 77953020053     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2010.04.008     Document Type: Article

References (33)

1. Bakos E., Evers R., Szakacs G., Tusnady G.E., Welker E., Szabo K., de Haas M., van Deemter L., Borst P., Varadi A., Sarkadi B. Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. Journal of Biological Chemistry 1998, 273(48):32167-32175.
2. Baltes S., Gastens A.M., Fedrowitz M., Potschka H., Kaever V., Loscher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 2007, 52(2):333-346.
3. Brodie M.J., Schachter S.C., Kwan P. Fast facts: epilepsy 2005, 56-84. Health Press Limited, Oxford. third ed.
4. Crespi C.L., Fox L., Stocker P., Hu M., Steimel D.T. Analysis of drug transport and metabolism in cell monolayer systems that have been modified by cytochrome P4503A4 cDNA-expression. European Journal of Pharmaceutical Sciences 2000, 12(1):63-68.
5. Crowe A., Teoh Y.K. Limited P-glycoprotein mediated efflux for anti-epileptic drugs. Journal of Drug Targeting 2006, 14(5):291-300.
6. Glauser T.A., Cnaan A., Shinnar S., Hirtz D.G., Dlugos D., Masur D., Clark P.O., Capparelli E.V., Adamson P.C. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. The New England Journal of Medicine 2010, 362(9):843-845.
7. Gören M.Z., Onat F. Ethosuximide: from bench to bedside. CNS Drug Reviews 2007, 13(2):224-239.
8. Gottesman M.M., Pastan I. The multidrug transporter, a double-edged sword. Journal of Biological Chemistry 1988, 263(25):12163-12166.
9. Han Y., Chin Tan T.M., Lim L.Y. In vitro and in vivo evaluation of the effects of piperine on P-gp function and expression. Toxicology and Applied Pharmacology 2008, 230(3):283-289.
10. Hennessy M., Spiers J.P. A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharmacological Research 2007, 55(1):1-15.
11. Hung C.C., Chen C.C., Lin C.J., Liou H.H. Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenetics and Genomics 2008, 18(5):390-402.
12. Juliano R.L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochimica et Biophysica Acta 1976, 455(1):152-162.
13. Kimchi-Sarfaty C., Oh J.M., Kim I.W., Sauna Z.E., Calcagno A.M., Ambudkar S.V., Gottesman M.M. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007, 315(5811):525-528.
14. Kwan P., Brodie M.J. Early identification of refractory epilepsy. New England Journal of Medicine 2000, 342(5):314-319.
15. Kwan P., Brodie M.J. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 2005, 46(2):224-235.
16. Kwan P., Sills G.J., Butler E., Gant T.W., Brodie M.J. Differential expression of multidrug resistance genes in naïve rat brain. Neuroscience Letters 2003, 339:33-36.
17. Loscher W., Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nature Reviews 2005, 6(8):591-602.
18. Luna-Tortos C., Fedrowitz M., Loscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 2008, 46(6):1364-1375.
19. Luna-Tortos C., Rambeck B., Jurgens U.H., Loscher W. The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins. Pharmaceutical Research 2009, 26(11):2464-2470.
20. Pauli-Magnus C., von Richter O., Burk O., Ziegler A., Mettang T., Eichelbaum M., Fromm M.F. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. Journal of Pharmacology and Experimental Therapeutics 2000, 293(2):376-382.
21. Potschka H., Loscher W. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia 2001, 42(10):1231-1240.
22. Potschka H., Fedrowitz M., Loscher W. P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neuroscience Letters 2002, 327(3):173-176.
23. Regesta G., Tanganelli P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Research 1999, 34(2-3):109-122.
24. Rivers F., O'Brien T.J., Callaghan R. Exploring the possible interaction between anti-epilepsy drugs and multidrug efflux pumps; in vitro observations. European Journal of Pharmacology 2008, 598(1-3):1-8.
25. Rizzi M., Caccia S., Guiso G., Richichi C., Gorter J.A., Aronica E., Aliprandi M., Bagnati R., Fanelli R., D'Incalci M., Samanin R., Vezzani A. Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. Journal of Neuroscience 2002, 22(14):5833-5839.
26. Schinkel A.H. The physiological function of drug-transporting P-glycoproteins. Seminars in Cancer Biology 1997, 8(3):161-170.
27. Schinkel A.H., Wagenaar E., Mol C.A., van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. Journal of Clinical Investigation 1996, 97(11):2517-2524.
28. Sills G.J., Kwan P., Butler E., de Lange E.C., van den Berg D.J., Brodie M.J. P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice. Epilepsy & Behavior 2002, 3(5):427-432.
29. Thiel-Demby V.E., Humphreys J.E., St John Williams L.A., Ellens H.M., Shah N., Ayrton A.D., Polli J.W. Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay. Molecular Pharmaceutics 2009, 6(1):11-18.
30. Wang Q., Strab R., Kardos P., Ferguson C., Li J., Owen A., Hidalgo I.J. Application and limitation of inhibitors in drug-transporter interactions studies. International Journal of Pharmaceutics 2008, 356(1-2):12-18.
31. Weiss J., Kerpen C.J., Lindenmaier H., Dormann S.M., Haefeli W.E. Interaction of antiepileptic drugs with human P-glycoprotein in vitro. Journal of Pharmacology and Experimental Therapeutics 2003, 307(1):262-267.
32. West C.L., Mealey K.L. Assessment of antiepileptic drugs as substrates for canine P-glycoprotein. American Journal of Veterinary Research 2007, 68(10):1106-1110.
33. Zhang L., Lin G., Kovacs B., Jani M., Krajcsi P., Zuo Z. Mechanistic study on the intestinal absorption and disposition of baicalein. European Journal of Pharmaceutical Sciences 2007, 31(3-4):221-231.